Close
Solutions
Online Inquiry
Global Services

Physiological CAR Construction Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Based on the advanced technology and rich experience, Creative Biolabs has promoted one-stop CAR development service. We offer a variety of CAR products including scFv-based CAR and physiological CAR in order to meet your special needs.

Researchers have made a significant effort in the treatment of cancer. Chimeric antigen receptors (CAR) are one remarkable way with tumor specificity. Therefore, co-stimulation in CAR-T cells has been the focus of intense research over the last several years. The basic CAR consists of an antigen-binding domain, a short spacer region, a transmembrane domain and signaling domain. In the most of applications, single-chain variable fragments (scFv) are using receptor ligands. The CARs endow T cells antigen-specific recognition, activation and proliferation in an MHC-independent manner.

However, since many CAR constructions contain scFv of murine origin, there remains a risk of an immune response against the modified cells. The consequent anaphylaxis of CAR-T cells transfer also can't be ignored. These disadvantages limit the persistence of infused cells. Thus, besides the classical CAR, Creative Biolabs developed a physiological CAR, as known as receptor ligands CAR, which can recognize the bind tumor antigens such as HER3 and HER4. The physiological CAR consists of an antigen receptor and a CD3ζ intracellular signaling domain with/without a transmembrane and a spacer region, which can also be engineered into immune cells to target its ligands expressed on tumor cells. Applied in the field of adoptive immunotherapy, this approach increases the ability of T cells to recognize tumor associated targets and eliminate cancer cells. After the construction of physiological CAR, our scientists can offer you a series of services to complete your whole research, including but not limited to CAR cell in vitro assay, CAR preclinical in vivo assay and CAR clinical trials.

Our technical experts are looking forward to designing a customized strategy of physiological CAR construction and creaing real value to your projects. You will save yourself the cost and effort with the help of our experienced team. If you are interested in our physiological CAR construction service to support your CAR development program, please contact us by email and send us your detailed request.

Schematic of Physiological Chimeric Antigen Receptors

Fig.1 Schematic of Physiological Chimeric Antigen Receptors

Reference

Huan Shi, et al. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Molecular Cancer, 2014,13:219.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.